Pharmacovigilance and safety aspects of sevoflurane.
Kharasch
E D
ED
University of Washington, Seattle, USA.
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D018685:Anesthetics, Inhalation / Q000009:adverse effects / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002648:Child; D004341:Drug Evaluation; D004987:Ethers / Q000009:adverse effects / Q000378:metabolism; D005459:Fluorides / Q000009:adverse effects / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000009:adverse effects / Q000378:metabolism; D007668:Kidney / Q000187:drug effects; D008738:Methyl Ethers; D011358:Product Surveillance, Postmarketing / Q000379:methods; D012449:Safety; D000077149:Sevoflurane; D014481:United States; D014486:United States Food and Drug Administration
D018685:Anesthetics, Inhalation; D004987:Ethers; D006845:Hydrocarbons, Fluorinated; D008738:Methyl Ethers; D000077149:Sevoflurane; C078742:fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether; D005459:Fluorides